MEtformin and Lorcaserin for weighT Loss in Schizophrenia (MELT)
Study of Weight Loss Strategies in Schizophrenia
Sponsor: NIDDK
Enrolling: Male and Female Patients
Study Length: 12 Months
Clinic Visits: 17
IRB Number: 7334
U.S. Govt. ID: NCT02796144
Contact: Scott Stroup, M.D.: 646-774-8435 / Scott.Stroup@nyspi.columbia.edu
Additional Study Information: This research study is testing medication strategies for weight loss in individuals with schizophrenia or schizoaffective disorder. Participants will be randomly assigned (like a coin flip) to lorcaserin, lorcserin plus metformin, or placebo. All participants will be offered regular diet and exercise counseling. The study lasts one year.
This study is closed
Investigator
Scott Stroup, MD, MPH
Do You Qualify?
Do you have a diagnosis of schizophrenia or schizoaffective disorder? Yes No
Are you overweight? Yes No
Do you take metformin? Yes No
Do you have diabetes? Yes No
Are you taking any weight loss medicines? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Scott Stroup, M.D.
Scott.Stroup@nyspi.columbia.edu
646-774-8435
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE